Exelixis (EXEL) Change in Receivables (2013 - 2026)
Exelixis' (EXEL) quarterly Change in Receivables came in at $42.0 million in Q2 2026, up 160.75% year-on-year from $16.1 million in Q2 2025, and up 284.27% quarter-over-quarter from -$22.8 million in Q1 2026.
Exelixis (EXEL) Change in Receivables (2013 - 2026) Analysis & Trends
Exelixis' Change in Receivables history runs 14 years deep, the most recent figure standing at $42.0 million for Q2 2026.
- On a quarterly basis, Change in Receivables rose 160.75% year-over-year to $42.0 million in Q2 2026; TTM through Apr 2026 was $47.3 million, a 15.68% increase from a year earlier, with the FY2026 full-year figure at $21.4 million, down 23.44% from the prior year.
- Change in Receivables grew to $42.0 million in Q2 2026 per EXEL's latest filing, from -$22.8 million in the prior quarter.
- Across five years, Change in Receivables topped out at $156.0 million in Q2 2024 and bottomed at -$127.0 million in Q3 2024.
- The 5-year median for Change in Receivables is $3.2 million (2024), against an average of $2.8 million.
- Across the five-year window, Change in Receivables tumbled 27370.73% in 2023 and soared 18223.93% in 2024, its largest moves.
- Year by year, Change in Receivables stood at $41000.0 in 2022, then tumbled by 27370.73% to -$11.2 million in 2023, then sank by 1036.08% to -$127.0 million in 2024, then soared by 113.67% to $17.4 million in 2025, then jumped by 141.97% to $42.0 million in 2026.
- Per Business Quant, the three latest EXEL Change in Receivables figures stand at $42.0 million (Q2 2026), -$22.8 million (Q1 2026), and $17.4 million (Q4 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 75.30 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -39.80 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -1.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Exelixis | 14.44 Bn | 13.66 Bn | 590.86 Mn | 42.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 42.03 Mn |
| Apr 3, 2026 | 42.03 Mn |
| Jan 2, 2026 | -22.81 Mn |
| Jan 2, 2026 | -22.81 Mn |
| Oct 3, 2025 | 17.37 Mn |
| Oct 3, 2025 | 17.37 Mn |
| Jul 4, 2025 | 10.72 Mn |
| Jul 4, 2025 | 10.72 Mn |
| Apr 4, 2025 | 16.12 Mn |
| Apr 4, 2025 | 16.12 Mn |
| Jan 3, 2025 | -4.24 Mn |
| Jan 3, 2025 | -4.24 Mn |
| Sep 27, 2024 | -127.03 Mn |
| Sep 27, 2024 | -127.03 Mn |
| Jun 28, 2024 | 156.05 Mn |
| Jun 28, 2024 | 156.05 Mn |
| Mar 29, 2024 | 3.17 Mn |
| Mar 29, 2024 | 3.17 Mn |
| Dec 29, 2023 | -11.18 Mn |
| Dec 29, 2023 | -11.18 Mn |